Analyst Price Targets — IMDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:48 pm | — | Lake Street | $12.00 | $5.33 | TheFly | Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street |
| November 11, 2025 9:51 am | Mike Matson | Needham | $9.00 | $6.80 | StreetInsider | Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham |
| May 21, 2025 12:42 pm | Thomas Flaten | UBS | $8.00 | $3.07 | TheFly | OncoCyte price target raised to $8 from $5 at Lake Street |
| April 24, 2024 10:38 am | Mike Matson | Needham | $4.25 | $2.38 | StreetInsider | OncoCyte Corp (OCX) PT Raised to $4.25 at Needham |
| December 1, 2022 9:13 am | — | Lake Street | $10.00 | $9.44 | Benzinga | Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5 |
| November 18, 2022 5:05 am | — | Piper Sandler | $10.00 | $8.52 | Benzinga | Piper Sandler Downgrades OncoCyte to Neutral, Lowers Price Target to $0.5 |
| August 17, 2022 9:42 pm | David Westenberg | Piper Sandler | $30.00 | $17.48 | TheFly | OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler |
| August 11, 2022 10:43 am | — | Lake Street | $60.00 | $19.27 | Benzinga | Lake Street Maintains Buy on OncoCyte, Lowers Price Target to $3 |
| August 11, 2022 5:31 am | — | Needham | $42.00 | $19.02 | Benzinga | Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.1 |
| May 15, 2022 9:15 pm | David Westenberg | Piper Sandler | $28.00 | $22.60 | TheFly | OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler |
Latest News for IMDX
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland Three posters to be presented at the 63rd European Renal Association (ERA) Congress, June 3–6, 2026 in Glasgow, Scotland Favorable real-world evidence poster to be presented at the American Transplant Congress (ATC),…
Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026.
NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company's flagship GraftAssureTM assay technology.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMDX.
U.S. House Trading
No House trades found for IMDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.